{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:34:57Z","timestamp":1792892097108,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019693","name":"Universidade Federal da Fronteira Sul","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005667","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa e Inova\u00e7\u00e3o do Estado de Santa Catarina","doi-asserted-by":"publisher","award":["18\/2024"],"award-info":[{"award-number":["18\/2024"]}],"id":[{"id":"10.13039\/501100005667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005667","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa e Inova\u00e7\u00e3o do Estado de Santa Catarina","doi-asserted-by":"publisher","award":["2025TR001141"],"award-info":[{"award-number":["2025TR001141"]}],"id":[{"id":"10.13039\/501100005667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005667","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa e Inova\u00e7\u00e3o do Estado de Santa Catarina","doi-asserted-by":"publisher","award":["27\/2025"],"award-info":[{"award-number":["27\/2025"]}],"id":[{"id":"10.13039\/501100005667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Institutos Nacionais de Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004933","name":"Instituto Nacional de Ci\u00eancia e Tecnologia em Toxinas","doi-asserted-by":"publisher","award":["150185\/2026\\u20130"],"award-info":[{"award-number":["150185\/2026\\u20130"]}],"id":[{"id":"10.13039\/501100004933","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bcp.2026.118030","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T22:49:26Z","timestamp":1777762166000},"page":"118030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Targeting purinergic signaling and MTAP-associated metabolism in cancer: A functional immunometabolic convergence framework"],"prefix":"10.1016","volume":"250","author":[{"given":"Vandriel","family":"Pedone da Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelli","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine Raquel","family":"Richter Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike Valentim","family":"Buzatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuri Raiel","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Ant\u00f4nio","family":"Roman Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlev","family":"Boison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarete Dulce","family":"Bagatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Franco Vieira de Oliveira Maciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"162","key":"10.1016\/j.bcp.2026.118030_b0005","article-title":"From purines to purinergic signalling: molecular functions and human diseases","volume":"6","author":"Huang","year":"2021","journal-title":"Sig Transduct Target Ther."},{"issue":"9","key":"10.1016\/j.bcp.2026.118030_b0010","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.4049\/jimmunol.2001342","article-title":"Ectonucleotidases in inflammation, immunity and cancer","volume":"206","author":"Haas","year":"2021","journal-title":"J. Immunol."},{"issue":"31","key":"10.1016\/j.bcp.2026.118030_b0015","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1021\/acs.biochem.9b00448","article-title":"An exceptionally potent inhibitor of human CD73","volume":"58","author":"Bowman","year":"2019","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.bcp.2026.118030_b0020","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ccell.2019.10.007","article-title":"Adenosine metabolism: emerging concepts for cancer therapy","volume":"36","author":"Boison","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.118030_b0025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1124\/pharmrev.121.000528","article-title":"ATP and adenosine metabolism in c\u00e2ncer: exploitation for therapeutic gain","volume":"74","author":"Yegutkin","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2026.118030_b0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","article-title":"Extracellular ATP and P2 signalling in the tumour microenvironment","volume":"18","author":"Di Virgilio","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.118030_b0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11302-014-9427-2","article-title":"Purinergic signalling and inflammatory cells","volume":"10","author":"Burnstock","year":"2014","journal-title":"Purinergic Signalling"},{"issue":"1","key":"10.1016\/j.bcp.2026.118030_b0040","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118030_b0045","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/jnc.13724","article-title":"How does adenosine control neuronal dysfunction and neurodegeneration?","volume":"139","author":"Cunha","year":"2016","journal-title":"J. Neurochem."},{"issue":"7","key":"10.1016\/j.bcp.2026.118030_b0050","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1158\/0008-5472.CAN-22-2553","article-title":"CD73-dependent adenosine signaling drives immunosuppression in pancreatic cancer","volume":"83","author":"Faraoni","year":"2023","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118030_b0055","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1097\/JS9.0000000000002406","article-title":"P2X7 receptor promotes the growth and metastasis of gastric cancer by activating P13K\/AKT\/GSK-3 beta signaling (experimental research)","volume":"111","author":"Zhang","year":"2025","journal-title":"Int. J. Surg."},{"issue":"7","key":"10.1016\/j.bcp.2026.118030_b0060","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1021\/acs.jmedchem.4c03121","article-title":"Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers","volume":"68","author":"Pettus","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118030_b0065","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41590-025-02153-3","article-title":"Inhibition of ENT1 relieves intracellular adenosine-mediated T\u2009cell suppression in cancer","volume":"26","author":"Sanders","year":"2025","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118030_b0070","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3390\/ijms19030808","article-title":"ATP release channels","volume":"19","author":"Taruno","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118030_b0075","doi-asserted-by":"crossref","unstructured":"Fredholm BB, et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors\u2014An Update. Pharmacol Rev. 2011; 63(1): 1\u201334. https:\/\/doi.org\/10.1124\/pr.110.003285.","DOI":"10.1124\/pr.110.003285"},{"issue":"6","key":"10.1016\/j.bcp.2026.118030_b0080","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2016","journal-title":"Trends Mol. Med."},{"issue":"18","key":"10.1016\/j.bcp.2026.118030_b0085","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1016\/j.molcel.2021.08.030","article-title":"Metabolic channeling: predictions, deductions and evidence","volume":"81","author":"Pareek","year":"2021","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.bcp.2026.118030_b0090","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3390\/cells9112496","article-title":"Extracellular ATP: a target for c\u00e2ncer therapy","volume":"9","author":"Vultaggio-Poma","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.118030_b0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11302-022-09905-y","article-title":"et al","volume":"19","author":"Wang","year":"2023","journal-title":"Purinergic Signaling: a Potential Therapeutic Target for Ischemic Stroke."},{"issue":"8","key":"10.1016\/j.bcp.2026.118030_b0100","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking Antibodies Targeting the CD39\/CD73 Immunosuppressive Pathway Unleash Immune responses in Combination Cancer Therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep."},{"issue":"14","key":"10.1016\/j.bcp.2026.118030_b0105","doi-asserted-by":"crossref","first-page":"11759","DOI":"10.3390\/ijms241411759","article-title":"The clinical significance of CD73 in cancer","volume":"24","author":"Bach","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2026.118030_b0110","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.3390\/ijms19123837","article-title":"Targeting adenosine receptor signaling in cancer immunotherapy","volume":"19","author":"Sek","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.118030_b0115","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/biom12030418","article-title":"Adenosine-metabolizing enzymes, adenosine kinase and adenosine deaminase in cancer","volume":"12","author":"Zhulai","year":"2022","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.bcp.2026.118030_b0120","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.241463","article-title":"Compartmentalization of adenosine metabolism in cancer cells and its modulation during acute hypoxia","volume":"133","author":"Losenkova","year":"2020","journal-title":"J. Cell Sci."},{"issue":"8","key":"10.1016\/j.bcp.2026.118030_b0125","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1208875","article-title":"Targeting CD73 in the Tumor Microenvironment with MEDI9447","volume":"5","author":"Hay","year":"2016","journal-title":"OncoImmunology"},{"issue":"3","key":"10.1016\/j.bcp.2026.118030_b0130","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008594","article-title":"Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8+ T cells","volume":"13","author":"Shin","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"15","key":"10.1016\/j.bcp.2026.118030_b0135","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2017.35.15_suppl.3004","article-title":"Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1\/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients","volume":"35","author":"Fong","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118030_b0140","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","article-title":"Adenosine Receptor 2A Blockade increases the Efficacy of Anti\u2013PD-1 through Enhanced Antitumor T-cell responses","volume":"3","author":"Beavis","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118030_b0145","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.neo.2017.02.004","article-title":"A novel antagonist of the immune checkpoint protein adenosine A2a receptor restores tumor-infiltrating lymphocyte activity in the context of the tumor microenvironment","volume":"19","author":"Mediavilla-Varela","year":"2017","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.bcp.2026.118030_b0150","article-title":"The roles of CD73 in cancer","volume":"2014","author":"Gao","year":"2014","journal-title":"Biomed Res. Int."},{"issue":"8","key":"10.1016\/j.bcp.2026.118030_b0155","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c00133","article-title":"Discovery of TNG908: a selective brain-penetrant MTA-cooperative PRMT5 inhibitor","volume":"67","author":"Cottrell","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118030_b0160","doi-asserted-by":"crossref","DOI":"10.1093\/pcmedi\/pbad030","article-title":"Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas","volume":"6","author":"Jiang","year":"2023","journal-title":"Precis. Clin. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.118030_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102367","article-title":"Extracellular 5\u2032-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins","volume":"298","author":"Tang","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118030_b0170","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP Deletions in Cancer create Vulnerability to Targeting of the MAT2A\/PRMT5\/RIOK1 Axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep."},{"issue":"6278","key":"10.1016\/j.bcp.2026.118030_b0175","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2026.118030_b0180","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41467-022-29397-z","article-title":"MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers","volume":"13","author":"Alhalabi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118030_b0185","doi-asserted-by":"crossref","unstructured":"Fedoriw A, et al. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell. 2019; 36(1): 100-114.e25. https:\/\/doi.org\/ 10.1016\/j.ccell.2019.05.014.","DOI":"10.1016\/j.ccell.2019.05.014"},{"issue":"2","key":"10.1016\/j.bcp.2026.118030_b0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","article-title":"MAT2A Inhibition Blocks the growth of MTAP-Deleted Cancer Cells by reducing PRMT5-Dependent mRNA Splicing and Inducing DNA damage","volume":"39","author":"Kalev","year":"2021","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.bcp.2026.118030_b0195","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.3390\/cells14241964","article-title":"MTAP-null tumors: a comprehensive review on synthetic vulnerabilities and therapeutic strategies","volume":"14","author":"Subramaniam","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.118030_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1173356","article-title":"Methylthioadenosine phosphorylase deficiency in tumors: a compelling therapeutic target","volume":"11","author":"Fan","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118030_b0205","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.str.2012.10.001","article-title":"Crystal Structure of the Human Ecto-5\u2032-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling","volume":"20","author":"Knapp","year":"2012","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.bcp.2026.118030_b0210","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118030_b0215","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/pro.3280","article-title":"Improvements to APBS biomolecular solvation suite","volume":"27","author":"Jurrus","year":"2017","journal-title":"Protein Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118030_b0220","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bcp.2026.118030_b0225","doi-asserted-by":"crossref","unstructured":"Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0. J Chem Inf and Model. 2021; 61(8): 3891\u20133898. https:\/\/doi.org\/10.1021\/acs.jcim.1c00203.","DOI":"10.1021\/acs.jcim.1c00203"},{"issue":"6278","key":"10.1016\/j.bcp.2026.118030_b0230","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.118030_b0235","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective PRMT5 inhibitor with potency in lymphoma models","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"13","key":"10.1016\/j.bcp.2026.118030_b0240","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/0008-5472.CAN-18-1010","article-title":"MTAP loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation","volume":"79","author":"Hansen","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118030_b0245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","article-title":"Arginine methylation: the coming of age","volume":"65","author":"Blanc","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118030_b0250","doi-asserted-by":"crossref","unstructured":"Gjuka E, et al. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance. Cancer Cell. 2023; 41(10): 1774\u20131787.E9. https:\/\/doi.org\/10.1016\/j.ccell.2023.09.005.","DOI":"10.1016\/j.ccell.2023.09.005"},{"issue":"3","key":"10.1016\/j.bcp.2026.118030_b0255","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/pr.112.006361","article-title":"Adenosine kinase: exploitation for therapeutic gain","volume":"65","author":"Boison","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.118030_b0260","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/caff.2018.0019","article-title":"Adenosine kinase deficiency increases susceptibility to carcinogens","volume":"9","author":"El-Kharrag","year":"2019","journal-title":"J Caffeine Adenosine Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118030_b0265","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1002\/jcb.28281","article-title":"1\u03b1, 25-Dihydroxyvitamin D3 alters ectonucleotidase expression and activity in human cutaneous melanoma cells","volume":"120","author":"Bagatini","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118030_b0270","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/CIRCRESAHA.116.309726","article-title":"Purinergic Signaling in the Cardiovascular System","volume":"120","author":"Burnstock","year":"2017","journal-title":"Circ. Res."},{"issue":"9","key":"10.1016\/j.bcp.2026.118030_b0275","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Disc."},{"issue":"2","key":"10.1016\/j.bcp.2026.118030_b0280","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/pharmrev.121.000445","article-title":"International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: a further Update","volume":"74","author":"Ijzerman","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2026.118030_b0285","article-title":"Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation","volume":"16","author":"Majumder","year":"2025","journal-title":"Front. Immunol."},{"issue":"261","key":"10.1016\/j.bcp.2026.118030_b0290","article-title":"Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models","volume":"11","author":"Jiang","year":"2025","journal-title":"Cell Death Discov."},{"issue":"6","key":"10.1016\/j.bcp.2026.118030_b0295","article-title":"Targeting the adenosinergic axis in cancer immunotherapy: Insights into A2A and A2B receptors and novel clinical combination strategies","volume":"77","author":"Rodr\u00edguez-Pamp\u00edn","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"44","key":"10.1016\/j.bcp.2026.118030_b0300","doi-asserted-by":"crossref","first-page":"17960","DOI":"10.1073\/pnas.1209814109","article-title":"Crystal structure of the human PRMT5\u2013MEP50 complex","volume":"109","author":"Antonysamy","year":"2012","journal-title":"PNAS"},{"issue":"11","key":"10.1016\/j.bcp.2026.118030_b0305","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-Deleted Cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118030_bib306","doi-asserted-by":"crossref","unstructured":"Yang R, Elsaadi S, Misund K, Abdollahi P, Vandsemb EN, Moen SH, Kusnierczyk A, Slupphaug G, Standal T, Waage A, Sl\u00f8rdahl TS, R\u00f8 TB, Rustad E, Sundan A, Hay C, Cooper Z, Schuller AG, Woessner R, Borodovsky A, Menu E, B\u00f8rset M, Sponaas AM. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. J Immunother Cancer. 2020 May;8(1):e000610. doi: 10.1136\/jitc-2020-000610. PMID: 32409420; PMCID: PMC7239696.","DOI":"10.1136\/jitc-2020-000610"},{"key":"10.1016\/j.bcp.2026.118030_bib307","doi-asserted-by":"crossref","unstructured":"Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez- Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. Adenosine 2A receptor blockade as immunotherapy for treatment-refractory renal cell cancer. Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158\/2159-8290.CD-19-0980. Published electronically on November 15, 2019. PMID: 31732494; PMCID: PMC6954326.","DOI":"10.1158\/2159-8290.CD-19-0980"},{"key":"10.1016\/j.bcp.2026.118030_bib308","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1021\/acs.jmedchem.9b01713","article-title":"Discovery of potent and selective inhibitors of small non-nucleotide CD73 molecules","volume":"63","author":"Jeffrey","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118030_bib309","doi-asserted-by":"crossref","unstructured":"Zhou Y, Shen H, Wu M, Wang J, Wu Z, Fu F, Liu Y, Lu J, Yao Y, Luo N, Zhou S, Tan KS, Chen B, Wang D. Pharmacological, pharmacokinetic and toxicity characterization of a novel anti-CD73 therapeutic antibody, IBI325, for cancer immunotherapy. Int J Biol Macromol. 2023 Feb 28;229:158-167. doi: 10.1016\/j.ijbiomac.2022.12.258. Epub 2022 Dec 29. PMID: 36587633.","DOI":"10.1016\/j.ijbiomac.2022.12.258"},{"key":"10.1016\/j.bcp.2026.118030_bib310","doi-asserted-by":"crossref","unstructured":"Kaplinsky N, Williams K, Watkins D, Adams M, Stanbery L, Nemunaitis J. Regulatory role of CD39 and CD73 in tumor immunity. Future Oncol. 2024;20(19):1367-1380. doi : 10.2217\/fon-2023-0871. Epub 2024 Apr 23. PMID: 38652041; PMCID: PMC11321403.","DOI":"10.2217\/fon-2023-0871"},{"key":"10.1016\/j.bcp.2026.118030_bib311","doi-asserted-by":"crossref","unstructured":"Chen L, Li L, Zhou C, Chen X, Cao Y. Adenosine A2A receptor activation reduces brain metastasis via SDF-1\/CXCR4 axis and protects the blood-brain barrier. Mol Carcinog. 2020 Apr;59(4):390-398. doi: 10.1002\/mc.23161. Epub 2020 Feb 9. PMID: 32037613.","DOI":"10.1002\/mc.23161"},{"key":"10.1016\/j.bcp.2026.118030_bib312","doi-asserted-by":"crossref","unstructured":"Yan P, Sun J, Guo J, Hu X, Zhou J, Xie X, Chen X, Luo H, Liu H, Tian Y. Inhibition of adenosine\/A2A receptor signaling suppresses dermal fibrosis by increasing fatty acid oxidation. Cell Community Signal. 2025 Apr 29;23(1):206. doi: 10.1186\/s12964-025-02210-2. PMID: 40301970; PMCID: PMC12042438.","DOI":"10.1186\/s12964-025-02210-2"},{"key":"10.1016\/j.bcp.2026.118030_bib313","doi-asserted-by":"crossref","unstructured":"Affronti HC, Long MD, Rosario SR, Gillard BM, Karasik E, Boerlin CS, Pellerite AJ, Foster BA, Attwood K, Pili R, Wilton JH, Campbell MJ, Smiraglia DJ. Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model. Oncotarget. 2017 Oct 20;8(61):103758-103774. doi: 10.18632\/oncotarget.21911. PMID: 29262598; PMCID: PMC5732764.","DOI":"10.18632\/oncotarget.21911"},{"key":"10.1016\/j.bcp.2026.118030_bib314","doi-asserted-by":"crossref","unstructured":"Bistulfi G, Affronti HC, Foster BA, Karasik E, Gillard B, Morrison C, Mohler J, Phillips JG, Smiraglia DJ. The essential role of methylthioadenosine phosphorylase in prostate cancer. Oncotarget. 2016 Mar 22;7(12):14380-93. doi: 10.18632\/oncotarget.7486. PMID: 26910893; PMCID: PMC4924722.","DOI":"10.18632\/oncotarget.7486"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:39:19Z","timestamp":1792888759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226003631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":70,"alternative-id":["S0006295226003631"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118030","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting purinergic signaling and MTAP-associated metabolism in cancer: A functional immunometabolic convergence framework","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118030"}}